


Seasonal Influenza Vaccines

H. Keipp Talbot, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices

June 24, 2021



Influenza Work Group

ACIP Members

Keipp Talbot (Chair)
Kevin Ault
Hank Bernstein
Camille Kotton

Ex Officio Members

Michael Cooper (NIH)
Cynthia Nolletti (FDA)
Chris Roberts (NIH)
Susan Wollersheim (FDA)

Liaison Representatives and Consultants

Robert Atmar
Ed Belongia
Sarah Coles
Buddy Creech
Sarah Despres
Jeff Duchin
Sandra Fryhofer
Robyn Harrison
Denise Jamieson
Wendy Keitel
Marie-Michèle Léger
Jamie Loehr
Susan Lett

Mark Mulligan
Flor Munoz
Kathy Neuzil
William Schaffner
Rob Schechter
Ken Schmader
Patsy Stinchfield
Tamara Sheffield
Angela Sinilaite
Peter Szilagyi
Chip Walter
Matthew Zahn

Recent WG Discussion

- Developed proposed updates to the ACIP influenza statement for 2021-22
 - Timing of vaccination
 - Co-administration of influenza vaccines with COVID-19 vaccines
 - Contraindications and precautions
 - Change in age indication of Flucelvax Quadrivalent from ages 4 years and older to ages 2 years and older (approved March, 2021)
- Presentation of results from an immunogenicity and safety study of Flucelvax Quadrivalent (cell culture-based inactivated influenza vaccine) among children 6 through 47 months of age
 - Currently approved for ages 2 years and older

Session Overview

- **Flucelvax Quadrivalent (cclIV4) Phase III Randomized Controlled Trial—
Immunogenicity and Safety in Children 6 through 47 months**
 - Dr. Gregg Sylvester (Seqirus)

- **WG considerations and proposed recommendations**
 - Lisa Grohskopf (CDC/NCIRD/Influenza Division)